Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
05:02pm, Wednesday, 28'th Sep 2022
Teva is a solid company which faces/faced headwinds from their high debt load and opioid crisis settlement uncertainty. But with most of the settlement uncertainty behind them and their efforts to sig
Teva Pharm expects to start paying U.S. opioid settlement in 2023 - CEO
04:57am, Sunday, 18'th Sep 2022
Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday.
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike
04:21am, Sunday, 18'th Sep 2022
The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Luce
Adderall is running low nationwide amid soaring demand -- here's how ADHD patients are coping
09:48pm, Friday, 16'th Sep 2022 MarketWatch
Patients with attention-deficit hyperactivity disorder are having trouble filling prescriptions of Adderall and generic versions of the drug amid growing demand and a shortage of the medication, acc
Teva Pharmaceutical: Past Behind And A Promising 2023
06:00pm, Friday, 16'th Sep 2022
Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 bil
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
08:30am, Monday, 12'th Sep 2022 Zacks Investment Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
04:13pm, Friday, 09'th Sep 2022 Zacks Investment Research
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
01:33pm, Friday, 09'th Sep 2022
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
08:59am, Thursday, 18'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced it plans to explore the potential development of a novel monkeypox vac
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
05:04pm, Wednesday, 17'th Aug 2022 Benzinga
Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.
Blueprint Medicines Corporation (NASDAQ: BPMC) fell 22.5% to $53.11 af
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
04:03pm, Wednesday, 17'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
02:05pm, Monday, 15'th Aug 2022 Zacks Investment Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
05:25am, Sunday, 07'th Aug 2022 Seeking Alpha
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
01:25am, Sunday, 07'th Aug 2022
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.
Why Teva Stock Trounced the Market on Friday
09:04pm, Friday, 05'th Aug 2022 The Motley Fool
Bank of America finds its inner bull with the generics producer.
